Founded in 2005, Capricor Therapeutics is a clinical-stage biotech company that focuses on discovering, developing, and commercializing cell and exosome-based therapeutics for the treatment and prevention of serious diseases such as Duchenne muscular dystrophy and COVID-19. Its lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also exploring the potential of exosome-based candidates to treat or prevent a variety of disorders, and has established itself as one of the leading companies investigating the field of exosome science. The company's innovative technology builds upon a large body of scientific research and enables them to approach the treatment of diseases in novel ways.